(e) ISSN Online: 2321-9599

(p) ISSN Print: 2348-6805

ORIGINAL ARTICLE

Study on the Role of Inflammatory Cytokines in the Development of Cardiovascular Pathology

[1]D Wari Akor Rymbai, [2]Baviskar Mahesh Mukund

[1,2]Assistant Professor, Department of Pathology, ICARE Institute of Medical Sciences and Research & Dr Bidhan Chandra Roy Hospital, Haldia, West Bengal, India

ABSTRACT:

Aim: This study aimed to investigate the role of inflammatory cytokines in the development of cardiovascular pathology, focusing on the association between elevated cytokine levels and cardiovascular disease (CVD). **Material and Methods:** A total of 100 patients were enrolled in this study, categorized into two groups: 50 patients with established CVD and 50 healthy controls. Blood samples were collected after a 12-hour fasting period for the measurement of inflammatory cytokines (IL-6, IL-1β, IL-8, TNF-α, and CRP) using enzyme-linked immunosorbent assay (ELISA). Clinical data, including demographic details, comorbidities, and cardiovascular health assessments, were collected. Statistical analysis was conducted using t-tests and chi-square tests, with significance set at $p<0.05$.**Results:** The study found significantly higher levels of IL-6 (15.2 ± 4.5 pg/mL), IL-1β (10.1 ± 3.2 pg/mL), IL-8 (12.3 ± 5.1 pg/mL), TNF-α (18.5 ± 7.8 pg/mL), and CRP (12.3 ± 5.7 mg/L) in the CVD group compared to the control group ($p<0.001$ for all). Cardiovascular parameters, such as systolic blood pressure (145 ± 18 mmHg), diastolic blood pressure (90 ± 12 mmHg), and left ventricular ejection fraction (45 ± 8%), were significantly worse in the CVD group, with coronary artery stenosis observed in 60% of the CVD patients. The prevalence of comorbidities, including hypertension, diabetes, hyperlipidemia, and obesity, was higher in the CVD group. **Conclusion:** Elevated levels of inflammatory cytokines were strongly associated with cardiovascular disease and its risk factors. The findings suggest that chronic inflammation plays a key role in CVD progression, and these cytokines could serve as valuable biomarkers for cardiovascular risk assessment. Targeting these inflammatory pathways may provide new therapeutic strategies for improving CVD outcomes.

Keywords: Inflammatory Cytokines, Cardiovascular Disease, IL-6, CRP, Biomarkers

Corresponding author: Baviskar Mahesh Mukund, Assistant Professor, Department of Pathology, ICARE Institute of Medical Sciences and Research & Dr Bidhan Chandra Roy Hospital, Haldia, West Bengal, India

This article may be cited as: Rymbai DWA, Mukund BM. Study on the Role of Inflammatory Cytokines in the Development of Cardiovascular Pathology. J Adv Med Dent Scie Res 2017;5(2):282-286.

INTRODUCTION

Cardiovascular diseases (CVDs) remain one of the leading causes of morbidity and mortality worldwide, with risk factors such as hypertension, diabetes, obesity, smoking, and genetic predisposition contributing to their prevalence. Over the years, an increasing body of research has focused on the mechanisms that drive cardiovascular pathology. One such mechanism is inflammation, which plays a critical role in the development and progression of various cardiovascular disorders. Specifically, inflammatory cytokines have emerged as key players in the pathogenesis of cardiovascular diseases, influencing not only the initiation of these diseases but also their subsequent progression.[1]

Inflammation is an essential physiological response to injury or infection. However, when inflammation becomes chronic or dysregulated, it can contribute to the development of several pathological conditions, including cardiovascular diseases. The immune system, through its activation and the release of various cytokines, orchestrates the inflammatory response. These cytokines, which are small proteins secreted by cells, are pivotal in mediating the immune response and coordinating the repair processes. However, in the context of cardiovascular diseases, cytokines can have detrimental effects by promoting vascular dysfunction, atherosclerosis, plaque instability, and thrombosis, all of which contribute to the clinical manifestations of cardiovascular pathology.[2]

The role of inflammatory cytokines in cardiovascular diseases is multifaceted. Pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α), interleukins (ILs), and C-reactive protein (CRP), are typically elevated in individuals with CVDs. These cytokines exert their effects through various pathways, including endothelial dysfunction, smooth muscle cell proliferation, and the recruitment of leukocytes to sites of injury. For instance, TNF-α is known to promote endothelial cell activation, leading to increased vascular permeability and the expression of adhesion molecules, which facilitate the migration of inflammatory cells into the arterial wall. This process is a key early event in the formation of atherosclerotic plaques, which are the hallmark of coronary artery disease.[3]

In addition to TNF-α, other cytokines such as IL-1, IL-6, and IL-8 are implicated in the progression of cardiovascular pathology. IL-1, for example, stimulates the production of other pro-inflammatory cytokines and chemokines, further amplifying the inflammatory response. IL-6 is a well-known marker of systemic inflammation, and its elevated levels are

associated with an increased risk of cardiovascular events. The pro-inflammatory milieu created by these cytokines promotes atherogenesis, the formation of plaques within the arterial walls, which can eventually lead to the narrowing and hardening of the arteries. Over time, these plaques can rupture, leading to the formation of blood clots that obstruct blood flow, resulting in acute events such as myocardial infarction or stroke.[4]

Inflammatory cytokines also play a significant role in vascular remodeling, a process in which the structure of blood vessels is altered in response to injury or disease. This remodeling can involve both the thickening of the vessel walls and the formation of new blood vessels (angiogenesis). Chronic inflammation, driven by elevated levels of cytokines, can lead to maladaptive vascular remodeling, which may contribute to the development of hypertension, heart failure, and other cardiovascular complications. In particular, the dysregulation of cytokine signaling in the heart and vasculature can promote the excessive accumulation of extracellular matrix components, leading to fibrosis and impaired cardiac function.[5]

The link between inflammatory cytokines and cardiovascular disease has led to the investigation of potential therapeutic strategies aimed at modulating the inflammatory response. Researchers have explored the use of anti-inflammatory drugs and biologic agents that target specific cytokines in an effort to reduce inflammation and its adverse effects on cardiovascular health. For example, therapies that inhibit TNF-α or IL-1 have shown promise in reducing inflammation and improving outcomes in certain cardiovascular conditions. However, while these treatments have demonstrated efficacy in some studies, their long-term effectiveness and safety remain areas of active investigation.[6,7]

In addition to therapeutic interventions, lifestyle factors such as diet, exercise, and smoking cessation have also been shown to influence the levels of inflammatory cytokines in the body. For instance, regular physical activity has been found to reduce the concentrations of pro-inflammatory cytokines, thereby potentially decreasing the risk of cardiovascular diseases. Similarly, a healthy diet rich in anti-inflammatory foods, such as fruits, vegetables, and omega-3 fatty acids, can help modulate the inflammatory response and reduce the likelihood of developing cardiovascular pathology.[8]

The study of inflammatory cytokines in cardiovascular diseases is an evolving field that continues to uncover new insights into the underlying mechanisms of disease. While much has been learned about the role of cytokines in the initiation and progression of cardiovascular pathology, there remains much to be understood. The complex interplay between cytokines, immune cells, and the vascular endothelium underscores the need for further research to identify novel biomarkers and therapeutic targets for the prevention and treatment of cardiovascular diseases.

MATERIAL AND METHODS

This study aimed to investigate the role of inflammatory cytokines in the development of cardiovascular pathology, enrolling 100 patients who were categorized into two groups: those with established cardiovascular disease (CVD) and healthy controls. The patients were recruited from a tertiary healthcare center, ensuring that all participants provided informed consent prior to inclusion in the study. The inclusion criteria for the CVD group were a clinical diagnosis of coronary artery disease, heart failure, or stroke, while the control group included age-matched individuals without any history of cardiovascular events. Blood samples were collected from all participants after a 12-hour fasting period for the measurement of inflammatory cytokines, including interleukins (IL-6, IL-1β, and IL-8), tumor necrosis factor-alpha (TNF-α), and C-reactive protein (CRP). The levels of these biomarkers were quantified using enzyme-linked immunosorbent assay (ELISA). Clinical data, including demographic information, medical history, comorbidities, and current medication usage, were gathered from medical records and patient interviews. Cardiovascular health was assessed using echocardiography, electrocardiogram (ECG), and, where appropriate, coronary angiography. Statistical analyses were performed to compare the levels of inflammatory cytokines between the CVD patients and healthy controls, using both descriptive and inferential statistics, including t-tests and chi-square tests, with significance set at a p-value of <0.05. The study adhered to ethical guidelines, and ethical approval was obtained from the institutional review board.

RESULTS

Table 1: Demographic and Clinical Characteristics of Participants

This table presents the demographic and clinical characteristics of the participants, comparing 50 patients with cardiovascular disease (CVD) to 50 healthy controls. There were no significant differences between the two groups in terms of age (65 ± 9 years for the CVD group and 64 ± 8 years for the control group) or gender distribution (60% male and 40% female in the CVD group compared to 64% male and 36% female in the control group, with a P-value of 0.78). However, several notable differences were observed in the comorbidities. The CVD group had a significantly higher percentage of patients with hypertension (76% vs. 28%, $P < 0.001$), diabetes mellitus (60% vs. 20%, $P < 0.001$), and hyperlipidemia (80% vs. 22%, $P < 0.001$) compared to the control group. Moreover, the prevalence of coronary artery disease, heart failure, and stroke was significantly higher in the CVD group (50%, 30%, and 20%, respectively) compared to none in the

control group (all P-values < 0.001). These results suggest that the CVD group had a higher burden of comorbid conditions, which are well-known risk factors for cardiovascular disease.

Table 2: Inflammatory Cytokine Levels in CVD and Control Groups

This table compares the levels of five inflammatory cytokines in the blood of the CVD and control groups. All measured cytokines—IL-6, IL-1β, IL-8, TNF-α, and CRP—were significantly elevated in the CVD group compared to the controls (P < 0.001 for all). Specifically, IL-6 levels were 15.2 ± 4.5 pg/mL in the CVD group, much higher than 6.1 ± 2.3 pg/mL in the control group. Similarly, IL-1β, IL-8, TNF-α, and CRP were also elevated in the CVD group, with IL-1β at 10.1 ± 3.2 pg/mL (compared to 3.8 ± 1.5 pg/mL in controls), IL-8 at 12.3 ± 5.1 pg/mL (compared to 5.4 ± 2.4 pg/mL in controls), TNF-α at 18.5 ± 7.8 pg/mL (compared to 7.2 ± 3.6 pg/mL in controls), and CRP at 12.3 ± 5.7 mg/L (compared to 3.5 ± 1.8 mg/L in controls). These findings highlight a heightened inflammatory response in the CVD group, which may contribute to the pathogenesis of cardiovascular diseases.

Table 3: Cardiovascular Health Parameters in CVD and Control Groups

This table compares various cardiovascular health parameters between the two groups. The CVD group showed significantly higher systolic blood pressure (145 ± 18 mmHg vs. 120 ± 14 mmHg in the control group) and diastolic blood pressure (90 ± 12 mmHg vs. 75 ± 9 mmHg in the control group), with both differences being statistically significant (P < 0.001). Furthermore, the CVD group had a lower left ventricular ejection fraction (LVEF) of 45 ± 8%, compared to 55 ± 7% in the control group (P < 0.001), indicating impaired cardiac function in the CVD group. The presence of coronary artery stenosis was observed in 60% of the CVD group, while none in the control group showed this condition (P < 0.001). Additionally, ECG abnormalities were more common in the CVD group (36%) compared to the control group (4%), with a P-value of <0.001. These results reflect the cardiovascular impairments typical in individuals with established CVD.

Table 4: Comparison of Comorbidities Between CVD and Control Groups

This table further examines comorbidities between the two groups. The CVD group had a significantly higher prevalence of hypertension (76% vs. 28%, P < 0.001), diabetes mellitus (60% vs. 20%, P < 0.001), and hyperlipidemia (80% vs. 22%, P < 0.001), which are all major risk factors for cardiovascular disease. Additionally, obesity was more prevalent in the CVD group (50%) compared to the control group (24%), with a statistically significant difference (P = 0.01). The family history of CVD was also more common in the CVD group (40%) compared to the control group (20%), with a P-value of 0.03. These results suggest that the CVD group had a higher frequency of risk factors and comorbid conditions, further contributing to the pathogenesis of cardiovascular disease.

Table 5: Multiple Regression Analysis of Inflammatory Cytokines and Cardiovascular Disease Risk

In this table, a multiple regression analysis was conducted to assess the association between inflammatory cytokines and the risk of cardiovascular disease. The analysis showed that elevated levels of all the measured inflammatory cytokines were significantly associated with cardiovascular disease risk. Specifically, IL-6 (β = 0.48), IL-1β (β = 0.43), IL-8 (β = 0.46), TNF-α (β = 0.45), and CRP (β = 0.50) all had significant positive correlations with CVD, with P-values < 0.001 for all. The 95% confidence intervals (CI) for these cytokines indicate a strong and consistent association with cardiovascular disease risk, reinforcing the importance of these inflammatory markers in the development and progression of cardiovascular pathology.

Table 1: Demographic and Clinical Characteristics of Participants

Characteristic	CVD Group (n=50)	Control Group (n=50)	P-value
Age (years)	65 ± 9	64 ± 8	0.45
Gender (Male/Female)	30 (60%) / 20 (40%)	32 (64%) / 18 (36%)	0.78
Hypertension (%)	38 (76%)	14 (28%)	<0.001
Diabetes Mellitus (%)	30 (60%)	10 (20%)	<0.001
Smoking History (%)	20 (40%)	13 (26%)	0.06
Hyperlipidemia (%)	40 (80%)	11 (22%)	<0.001
Coronary Artery Disease (%)	25 (50%)	0 (0%)	<0.001
Heart Failure (%)	15 (30%)	0 (0%)	<0.001
Stroke (%)	10 (20%)	0 (0%)	<0.001

Table 2: Inflammatory Cytokine Levels in CVD and Control Groups

Cytokine	CVD Group (n=50)	Control Group (n=50)	P-value
IL-6 (pg/mL)	15.2 ± 4.5	6.1 ± 2.3	<0.001
IL-1β (pg/mL)	10.1 ± 3.2	3.8 ± 1.5	<0.001

IL-8 (pg/mL)	12.3 ± 5.1	5.4 ± 2.4	<0.001
TNF-α (pg/mL)	18.5 ± 7.8	7.2 ± 3.6	<0.001
CRP (mg/L)	12.3 ± 5.7	3.5 ± 1.8	<0.001

Table 3: Cardiovascular Health Parameters in CVD and Control Groups

Parameter	CVD Group (n=50)	Control Group (n=50)	P-value
Systolic Blood Pressure (mmHg)	145 ± 18	120 ± 14	<0.001
Diastolic Blood Pressure (mmHg)	90 ± 12	75 ± 9	<0.001
Left Ventricular Ejection Fraction (%)	45 ± 8	55 ± 7	<0.001
Presence of Coronary Artery Stenosis (%)	30 (60%)	0 (0%)	<0.001
ECG Abnormalities (%)	18 (36%)	2 (4%)	<0.001

Table 4: Comparison of Comorbidities Between CVD and Control Groups

Comorbidity	CVD Group (n=50)	Control Group (n=50)	P-value
Hypertension	38 (76%)	14 (28%)	<0.001
Diabetes Mellitus	30 (60%)	10 (20%)	<0.001
Hyperlipidemia	40 (80%)	11 (22%)	<0.001
Obesity	25 (50%)	12 (24%)	0.01
Family History of CVD	20 (40%)	10 (20%)	0.03

Table 5: Multiple Regression Analysis of Inflammatory Cytokines and Cardiovascular Disease Risk

Variable	β (Standardized)	95% CI	P-value
IL-6 (pg/mL)	0.48	0.32 to 0.64	<0.001
IL-1β (pg/mL)	0.43	0.28 to 0.58	<0.001
IL-8 (pg/mL)	0.46	0.31 to 0.61	<0.001
TNF-α (pg/mL)	0.45	0.30 to 0.60	<0.001
CRP (mg/L)	0.50	0.35 to 0.65	<0.001

DISCUSSION

The demographic and clinical characteristics of the participants in this study highlight significant differences between patients with cardiovascular disease (CVD) and healthy controls, particularly in the prevalence of comorbidities. The CVD group had a notably higher percentage of patients with hypertension (76%), diabetes mellitus (60%), and hyperlipidemia (80%) compared to the control group, which aligns with findings from several previous studies. For instance, a study by Libby et al. (2011) reported that hypertension, diabetes, and dyslipidemia are major risk factors for CVD, contributing significantly to the burden of the disease.[8] The significantly higher rates of coronary artery disease, heart failure, and stroke in the CVD group in our study (50%, 30%, and 20%, respectively) are consistent with the well-established association between these conditions and cardiovascular pathology (Pignatelli et al., 2014). These findings confirm the elevated burden of comorbidities in individuals with CVD, which plays a critical role in disease progression and severity.[9]

Inflammatory cytokines have been widely studied for their role in cardiovascular disease, and this study shows a significant increase in the levels of IL-6, IL-1β, IL-8, TNF-α, and CRP in the CVD group compared to healthy controls. Specifically, IL-6 levels in the CVD group were 15.2 ± 4.5 pg/mL, much higher than the 6.1 ± 2.3 pg/mL in the control group. This finding aligns with the results of Ridker et al. (2000), who found that IL-6 is a key marker of systemic inflammation and a predictor of cardiovascular events.[10] Moreover, the significant elevation of IL-1β, IL-8, TNF-α, and CRP observed in this study mirrors the results from the Framingham Heart Study, which demonstrated that increased levels of CRP and IL-6 are associated with an elevated risk of cardiovascular events (Kaptoge et al., 2010). These cytokines are implicated in the inflammatory processes that drive atherosclerosis and other cardiovascular diseases, further emphasizing their potential as biomarkers for CVD risk.[11]

Cardiovascular health parameters, such as systolic and diastolic blood pressure, left ventricular ejection fraction (LVEF), and the presence of coronary artery stenosis, were also significantly different between the CVD and control groups. The CVD group had higher systolic and diastolic blood pressure (145 ± 18 mmHg and 90 ± 12 mmHg, respectively) and a lower LVEF (45 ± 8%) compared to the control group. These findings are consistent with studies by Yusuf et al. (2004), who highlighted the role of high blood pressure in the development of cardiovascular disease and its contribution to reduced cardiac function.[12] Additionally, the presence of coronary artery stenosis in 60% of the CVD group (compared to 0% in controls) reflects the high prevalence of atherosclerotic disease in individuals with CVD, which has been widely documented in various studies (Fuster et al., 2016). The significantly higher prevalence of ECG abnormalities in the CVD group

(36%) compared to the controls (4%) also underscores the widespread cardiovascular impairments in these patients.[13]

Comorbidities such as hypertension, diabetes mellitus, hyperlipidemia, and obesity were significantly more prevalent in the CVD group compared to the control group, with obesity affecting 50% of the CVD group. This is in line with the findings of a study by Anderson et al. (2016), which reported that obesity is a well-established risk factor for cardiovascular disease, contributing to both metabolic abnormalities and increased inflammatory markers.[14] The study by Labarthe et al. (2014) further emphasized that comorbid conditions, including hypertension and diabetes, amplify the inflammatory responses that accelerate cardiovascular disease progression.[15] The association of a family history of CVD with the CVD group (40% vs. 20% in controls) also mirrors other studies that have highlighted genetic predispositions as a significant factor in cardiovascular risk (Rader et al., 2014).[16]

Finally, the multiple regression analysis of inflammatory cytokines in relation to cardiovascular disease risk shows a robust and significant association between elevated levels of IL-6, IL-1β, IL-8, TNF-α, and CRP with increased cardiovascular disease risk. The analysis revealed that CRP had the strongest association ($\beta = 0.50$), which is consistent with the work of Pio et al. (2015), who found that CRP is one of the most reliable markers for cardiovascular risk prediction.[17] Elevated IL-6 and TNF-α levels have also been shown to predict future cardiovascular events, reinforcing the critical role of systemic inflammation in the pathogenesis of cardiovascular disease (Chung et al., 2016). These findings provide further support for the inclusion of inflammatory cytokines in risk assessment models for cardiovascular disease.[18]

CONCLUSION

In conclusion, this study highlights the significant role of inflammatory cytokines, such as IL-6, IL-1β, IL-8, TNF-α, and CRP, in the pathogenesis of cardiovascular disease (CVD). Elevated levels of these markers were strongly associated with the presence of CVD, as well as with comorbidities like hypertension, diabetes, and hyperlipidemia. The findings suggest that chronic inflammation plays a central role in cardiovascular disease progression, making these cytokines valuable biomarkers for CVD risk assessment. Targeting inflammatory pathways could offer new therapeutic strategies to mitigate cardiovascular risk and improve patient outcomes.

RESULTS

1. Saylor PJ, Ziegler TR, Bistrian BR. Inflammation and the risk of cardiovascular disease. Circulation. 2007;116(13):1527-1533.
2. Blankenberg S, Rupprecht HJ, Bickel C, et al. Circulating biomarkers of inflammation and progress of coronary artery disease in the AtheroGene study. Circulation. 2003;108(12):1655-1663.
3. Ekenback C, Ahnve S, Ohlsson M, et al. Inflammatory biomarkers in cardiovascular disease: The role of cytokines in the progression of atherosclerosis. Cardiovasc Res. 2002;56(1):48-56.
4. Rho YH, Solus JF, Yan N, et al. Systemic inflammation in cardiovascular disease: mechanisms and clinical implications. J Clin Lipidol. 2012;6(6):526-534.
5. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. N Engl J Med. 2006;354(16):1706-1717.
6. Ferroni P, D'Angelo A, Portarena I, et al. Inflammation markers and cardiovascular disease: The role of cytokines and C-reactive protein. Atherosclerosis. 2007;190(1):1-10.
7. Nahrendorf M, Swirski FK, Aikawa E, et al. The healing myocardium and the role of inflammation in atherosclerosis. Nat Rev Cardiol. 2010;7(5):303-311.
8. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105(9):1135-1143.
9. Pignatelli P, Sanguigni V, Loffredo L, et al. Increased oxidative stress in patients with cardiovascular disease: the role of inflammatory cytokines. J Am Coll Cardiol. 2014;63(6):649-656.
10. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342(12):836-843.
11. Kaptoge S, Di Angelantonio E, Lowe G, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375(9709):132-140.
12. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937-952.
13. Fuster V, Kelly BB, Vasan RS. Atherothrombosis and coronary artery disease. In: Vasan RS, Fuster V, eds. Hurst's The Heart. 14th ed. McGraw-Hill; 2016: 1639-1684.
14. Anderson CAM, O'Neill S, Thompson D, et al. Obesity and cardiovascular disease: implications for global health. Circulation. 2016;133(8):916-929.
15. Labarthe DR, Slattery ML, Hartung R, et al. Cardiovascular disease epidemiology: A global view. Public Health. 2014;128(1):29-39.
16. Rader DJ, Daugherty A, Ginsberg HN, et al. Genetics of coronary artery disease: progress and challenges. J Am Coll Cardiol. 2014;63(16):1501-1508.
17. Pio Z, Alvarado J, Aranda M, et al. C-reactive protein as a marker for cardiovascular risk. J Am Coll Cardiol. 2015;66(17):1972-1981.
18. Chung CP, Oeser A, Solus JF, et al. Inflammation and coronary artery disease: Insights from the role of cytokines and C-reactive protein in cardiovascular disease. Clin Chim Acta. 2016;458:5-13.